Pharmaceuticals News and Research

RSS

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease

29 May 2015

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs.

29 May 2015

Maetrics, Medical Cluster host innovative conference in Zurich, Switzerland

Maetrics, a leading international consulting firm focused on the life sciences sector, wrapped up a successful conference, "The cost of non-compliance -- How new regulation is reshaping the Medical Technology industry," today in Zurich.

29 May 2015

RI-MUHC researchers receive $1.5 million to develop glutamate biosensor platform for brain diseases

In the human brain and retina, glutamate is an important messenger that carries information from one neuron to another. The level of glutamate transmitted between neurons is crucial to cell communication: too high and neurons die, too low and the information is not communicated properly. In either case this can contribute to neurological diseases including stroke, glaucoma, and Alzheimer's.

29 May 2015

Study explores efficacy of selective serotonin reuptake inhibitors in reducing depressed mood

Many have recently questioned the efficacy of the most common antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs). The conclusion that these drugs are ineffective is however partly based on a misinterpretation of the outcome of the clinical trials once conducted to demonstrate their efficacy. This was the finding of a study conducted by researchers at the Sahlgrenska Academy.

29 May 2015

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.

29 May 2015

Sanford-Burnham, Takeda partner to develop new therapeutic targets for cardiovascular disease

Sanford-Burnham Medical Research Institute at Lake Nona today announced it has signed a two-year partnership agreement with Takeda Pharmaceutical Company Ltd. of Japan to study the potential role of several gene regulatory proteins as targets for the treatment of heart failure.

29 May 2015

iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics, today reported financial results for the quarter ended March 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 May 2015

Proteomics research market estimated to reach $1.6 billion this year

Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.

29 May 2015

UB researchers identify mechanisms behind some autistic behaviors, suggest potential targets

Scientists at the University at Buffalo have identified the mechanisms behind a genetic mutation that produces certain autistic behaviors in mice, as well as therapeutic strategies to restore normal behaviors.

28 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be discussed in a poster presentation at the 2015 ASCO Annual Meeting.

28 May 2015

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals, Inc. today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in the formation of new, abnormal (heterotopic) bone in muscles, tendons and ligaments.

28 May 2015

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

World MS Day was created by the Multiple Sclerosis International Foundation (MSIF) in 2009 to raise global awareness of MS...

28 May 2015

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

28 May 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.

28 May 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago.

27 May 2015

Six research teams awarded grant to accelerate discovery of new drugs for brain, nervous system disorders

CQDM, Brain Canada and the Ontario Brain Institute award close to $8.5M to six (6) multi-disciplinary and multi-provincial research teams across Canada to address unmet needs in neuroscience within their Focus on Brain strategic initiative. To this amount, $1.5M is added from the various research entities involved as in-kind contributions.

27 May 2015

Actavis creates collaborative program to improve care for patients with multidrug-resistant infections

Actavis plc, a leading global specialty pharmaceutical company committed to infectious disease treatment innovation, today announced the creation of SHARE ID (Sharing Hospital data to Advance Research and Enhance patient care in Infectious Diseases), a collaborative program to leverage real-world data to advance the delivery and effectiveness of care for patients with serious infections due to antibiotic-resistant pathogens.

27 May 2015

Scorpion venom could kill cancer cells

When the toxin invades channels in the cells with this disease produces cellular damage until killing them.

27 May 2015

Pharmaceuticals News and Research

First European approval of drug to treat genetic kidney disease ADPKD

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Maetrics, Medical Cluster host innovative conference in Zurich, Switzerland

RI-MUHC researchers receive $1.5 million to develop glutamate biosensor platform for brain diseases

Study explores efficacy of selective serotonin reuptake inhibitors in reducing depressed mood

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Sanford-Burnham, Takeda partner to develop new therapeutic targets for cardiovascular disease

iCo Therapeutics reports financial results for first quarter 2015

Proteomics research market estimated to reach $1.6 billion this year

UB researchers identify mechanisms behind some autistic behaviors, suggest potential targets

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

Six research teams awarded grant to accelerate discovery of new drugs for brain, nervous system disorders

Actavis creates collaborative program to improve care for patients with multidrug-resistant infections

Scorpion venom could kill cancer cells

Industry Focus - Biopharma eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring